Hjem › Ikke-småcellet lungekreft › North Carolina › Winston-Salem
Kliniske studier for Ikke-småcellet lungekreft i Winston-Salem, NC
12 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Winston-Salem (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi unna
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RekruttererFase 3
- Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RekruttererFase 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RekruttererFase 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
RekruttererFase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
RekruttererFase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
RekruttererFase 3
- Atrium Health Wake Forest Baptist, Winston-Salem
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
RekruttererObservasjonsstudie
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RekruttererFase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- Wake Forest NCORP Research Base, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi unna
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Winston-Salem
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Winston-Salem
- Kreft (alle typer)19 studier
- Akut myelogen leukemi18 studier
- Multipelt myelom14 studier
- Brystkreft14 studier
- Kardiovaskulær sykdom14 studier
- KOLS10 studier
- Eggstokkreft10 studier
- Type 2-diabetes9 studier
- Myelodysplastiske syndromer9 studier
- Glioblastom8 studier
- Kronisk lymfatisk leukemi8 studier
- Lungekreft8 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.